Evaluation of diagnostic performances of 18F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliomas : a phase IIIb exploratory trial - 2021PI203

Centre Hospitalier Regional Universitaire De Nancy0 个研究点目标入组 88 人开始时间: 2022年12月16日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Age between 18 and 75 years old, WHO general condition =2, Identification of an unifocal brain tumour at the initial diagnosis with no contrast in the MRI and suspected to be a LGG, with biopsy/surgery envisaged within 6 months of the PET scan/CT, MRI performed a maximum of 3 weeks before inclusion and comprising the conventional morphological sequences (T1, T1 sequences with injection of contrast agent and T2 FLAIR)., Subject affiliated to or beneficiary of a social security plan, Subject having received complete information on the organisation of the research and having signed the informed consent form.

•Multifocal brain lesions, Contraindication to 18F-FDOPA PET, Concomitant treatment by Carbidopa, Halopéridol, Réserpine and MAOIs., Pregnant, parturient women or nursing mothers under Article L1121-5, Women of childbearing age who do not have effective contraception under Article L1121-5, Monitoring not possible, Persons deprived of their liberty by a judicial or administrative decision under Article 1121-8, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1

发起方

Centre Hospitalier Regional Universitaire De Nancy